Entera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at th
Go back to Entera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at th| Entrx Corporation (NASDAQ: ENTX) | Delayed: 3.05 +0.03 (0.99%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.02 | 52 Week High | $0.30 | |||
| Open | $3.12 | 52 Week Low | $0.10 | |||
| Day High | $3.20 | P/E | N/A | |||
| Day Low | $2.96 | EPS | $0.00 | |||
| Volume | 784,598 | |||||



